Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately-Reference-Cited by-同舟云学术

Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately

Published:2021-10-01 Issue:19 Volume:60 Page:3061-3070
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Tojima Hiroki¹,Kakizaki Satoru¹,Takakusagi Satoshi²,Hoshino Takashi³,Naganuma Atsushi³,Nagashima Tamon⁴,Namikawa Masashi⁵,Ueno Takashi⁶,Shimada Yasushi⁶,Hatanaka Takeshi⁷,Takizawa Daichi⁸,Arai Hirotaka⁸,Sato Ken¹,Takagi Hitoshi²,Uraoka Toshio¹

Affiliation:

1. Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Japan

2. Department of Gastroenterology, Kusunoki Hospital, Japan

3. Department of Gastroenterology, National Hospital Organization Takasaki General Medical Center, Japan

4. Department of Gastroenterology, National Hospital Organization Shibukawa Medical Center, Japan

5. Department of Internal Medicine, Kiryu Kosei General Hospital, Japan

6. Department of Internal Medicine, Isesaki Municipal Hospital, Japan

7. Department of Gastroenterology, Gunma Saiseikai Maebashi Hospital, Japan

8. Department of Gastroenterology, Maebashi Red Cross Hospital, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/60/19/60_6591-20/_pdf

Reference33 articles.

1. 1. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12: 671-675, 1990.

2. 2. Ogawa E, Furusyo N, Nakamuta M, et al. Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: results from a multicenter, real-world cohort study. Hepatol Res 49: 617-626, 2019.

3. 3. Osawa M. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. 3-8, 2018.

4. 4. Kusakabe A, Kurosaki M, Itakura J, et al. Efficacy and safety of glecaprevir/pibrentasvir as retreatment therapy for patients with genotype 2 chronic hepatitis C who failed prior sofosbuvir plus ribavirin regimen. Hepatol Res 49: 1121-1126, 2019.

5. 5. D'Ambrosio R, Pasulo L, Puoti M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol 70: 379-387, 2019.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EVOLUTION OF FIBROSIS, INFLAMMATION, STEATOSIS AND STEATOHEPATITIS IN HCV INFECTED PATIENTS AFTER TREATMENT WITH DIRECT- ACTING ANTIVIRAL THERAPY (A FIBROMAX® ANALYSIS);Archiv Euromedica;2022-12-20

2. Importance of HCC surveillance among patients with hepatitis C who have achieved a sustained viral response but have dropped out of periodical follow up;Kanzo;2021-11-01